Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents

In recent years antagonists of very late antigen-4 (VLA4, also known as integrin α4β1) have shown great promise in treating inflammatory disorders in a number of animal models. The most advanced in this endeavor is a humanized anti-α4 antibody, Antegren (®), which is in phase II clinical trials for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current opinion in chemical biology 1998-08, Vol.2 (4), p.453-457
Hauptverfasser:	Lin, Ko-Chung, Castro, Alfredo C
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Animals Anti-Inflammatory Agents, Non-Steroidal - chemistry Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal - therapeutic use Clinical Trials as Topic Cyclization Drug Design Drug Evaluation Humans Integrin alpha4beta1 Integrins - antagonists & inhibitors Molecular Mimicry Molecular Sequence Data Peptides - chemistry Peptides - therapeutic use Receptors, Lymphocyte Homing - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In recent years antagonists of very late antigen-4 (VLA4, also known as integrin α4β1) have shown great promise in treating inflammatory disorders in a number of animal models. The most advanced in this endeavor is a humanized anti-α4 antibody, Antegren (®), which is in phase II clinical trials for multiple sclerosis. The first reported small-molecule VLA4 antagonist to advance into clinical trials is currently in phase I as an aerosol for treating asthma. A number of peptides, cyclic peptides and peptidomimetics have been disclosed and are in preliminary stages of development.
ISSN:	1367-5931 1879-0402
DOI:	10.1016/S1367-5931(98)80120-8